Shots:

• The P-III POETYK PSO-1 study involves assessing deucravacitinib (6mg- qd) vs PBO & Otezla (apremilast) in 666 patients with moderate to severe plaque psoriasis
• The trial met its co-1EPs & 2EPs demonstrating deucravacitinib was superior to Otezla (apremilast) in the patients reaching a PASI 75 and sPGA 0/1 @16wks. The overall safety profile of deucravacitinib was consistent with previously reported P-II results
• Deucravacitinib (BMS-986165- PO) is the first & only novel selective TYK2 inhibitor- currently being evaluated in psoriasis- PsA- lupus- and IBD

  Ref: Businesswire | Image: BMS